Taxol, a pivotal chemotherapy drug, has benefitted millions suffering from ovarian, breast, and lung cancers. Traditionally sourced from yew trees, its production faces challenges due to the slow growth of these trees, which yield a meager amount of the drug. Moreover, the complex structure of Taxol makes synthetic manufacturing costly and complicated. To overcome this hurdle, scientists have been investigating the enzymes responsible for Taxol synthesis in yew trees since the 1990s, aiming to transfer this biological knowledge to more efficient organisms like yeast.
Recently, a research team led by Conor McClune, a postdoctoral scholar in chemical engineering, made significant strides in this area. They discovered new insights into the plant genes involved in Taxol production, potentially speeding up the path toward efficient drug synthesis. In their study published in Nature on June 11, Elizabeth Sattely, the senior author and associate professor of chemical engineering, described Taxol as “the holy grail of biosynthesis in the plant natural products world.” This groundbreaking research offers hope for a bioproduction strategy that could revolutionize Taxol manufacturing.
Understanding the intricate workings of yew trees has proven difficult due to their vast genome of approximately 50,000 genes, compared to just 4,000 in a bacterium like E. coli. Prior to this study, only 12 genes responsible for Taxol production had been identified, and progress was stymied. To streamline their search, the Stanford team developed a novel method to filter through the large number of enzymes involved in Taxol synthesis. They stressed yew tree needle samples using hormones and microbes to stimulate the production of defensive compounds, including Taxol.
By isolating around 10,000 cellular nuclei from the yew needles and sequencing their messenger RNA, the researchers identified which genes were active under stress. This allowed them to discern patterns of gene activation that indicated potential partnerships in producing the essential proteins for Taxol synthesis. Following this, they inserted promising genes into tobacco plants to determine their role in facilitating the crucial chemical reactions.
The results were promising, uncovering eight new critical genes, including FoTO1, which played a key role in streamlining the synthesis process. Remarkably, these tobacco plants were able to produce baccatin III, a precursor to Taxol, at higher concentrations than those found in yew trees. McClune noted, “Theoretically, with a little more tinkering, we could really make a lot of this and no longer need the yew at all to get baccatin.”
The research also revealed an enzyme that catalyzes one of the final steps in the transformation from baccatin III to Taxol, leaving just two more steps to complete the synthesis. Coincidentally, researchers at the University of Copenhagen identified these remaining enzymes in April. With 22 genes identified, the team is now closer to uncovering the complete blueprint for synthesizing Taxol from scratch.
Future plans involve testing these final two enzymes in tobacco plants to confirm their efficacy in conjunction with the other 20 genes. If successful, these genes could be integrated into yeast, transforming them into efficient production facilities capable of generating Taxol at a commercial scale. This innovative approach could also pave the way for exploring the genetic makeup of other plant species, opening new doors in the understanding of plant chemistry.
Overall, this research not only offers a promising avenue for more efficient cancer treatment but also exemplifies the strides being made in biotechnological innovation within the field of natural products. The study received support from the Howard Hughes Medical Institute, the National Institutes of Health, and the Damon Runyon Cancer Research Foundation.
Original Source: https://news.stanford.edu/stories/2025/06/yew-tree-enzymes-research-cancer-drug-taxol
Category :
Tags:
Publish Date: 2025-06-18 03:10:00
